New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Volume 2, # 4 - August, 1996

Table of Contents

STATE-OF-THE-ART MANAGEMENT OF CANCER
BREAST CANCER-PART I
Epidemiology 334
Pathogenesis of Breast Cancer 334
Breast Cancer Etiology and Risk Factors 335
  Age 336
  Hormonal Risk Factors 336
  Inherited Breast Cancer 337
    ATM 337
    BRCA1 337
    BRCA2339
  Dietary, Environmental and Other Factors339
  Molecular Markers 340
MEETING COVERAGE
RECENT DEVELOPMENTS IN NUCLEAR MEDICINE
From the 43rd Annual Meeting of the Society of Nuclear Medicine
Denver, CO, June 3-6, 1996
Coincidence Imaging and Expanded Use of FDG340
  ADAC Laboratories MCD Camera 340
  Hot Spot Imaging 341
  Staging of Cancer 342
Breast Scintigraphy to Differentiate Benign from Malignant Lesions 342
Cancer Imaging with Monoclonal Antibodies and Peptides 342
  Monoclonal Antibody-based Agents 342
    Antisoma 342
    Biomira 342
    Cytogen 342
    Immunomedics 343
    Neoprobe 344
    NeoRx 344
  Radiolabeled Peptides 345
    Mallinckrodt 345
    Diatide 345
TECHNOLOGY UPDATE
CANCER VACCINES: HUMORAL VERSUS CELLULAR IMMUNITY
Rationale for Cancer Vaccine Development 345
Human Immune Response346
Vaccines Eliciting a Cellular (T cell) Immune Response 347
  Active Specific Immunotherapy (ASI)348
    Biomira 348
    ImmunoTherapy Corporation348
    Progenics Pharmaceuticals 349
  ASI Using Anti-Idiotypic Antibodies 349
    ImClone Systems 350
  Passive Immunotherapy 350
    Centocor 351
Vaccines Eliciting a Cellular (T cell) Immune Response 351
  Tumor Antigen Vaccines 352
    Cytel 352
    Lidak Pharmaceuticals 353
  Heat Shock Proteins 353
    Antigenics 353
    StressGen Biotechnologies353
  Adoptive (Cellular) Immunotherapy 353
Cancer Vaccines that Stimulate Both vHumoral and Cell-Mediated Immunity 353
  Allogeneic Tumor Cell Vaccines 354
    Ribi ImmunoChem Research 354
  Gene Transfer Into Tumor Cells 354
    Somatix Therapy 355
    Therion Biologics 355
    Vical 355
Potential Markets for Cancer Vaccines 355

HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887